In this research study, the investigators are looking to determine the effectiveness of
Pembrolizumab (MK-3475) when given with bevacizumab or when given alone for the treatment of
recurrent glioblastoma multiforme (GBM). This study will also test the safety and
tolerability of Pembrolizumab (MK-3475) when given alone or with bevacizumab.